- Home
- RIV vs NMRA Comparison
RIV vs NMRA Comparison
Compare RIV & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- NMRA
- Stock Information
- Founded
- RIV 2015
- NMRA 2019
- Country
- RIV United States
- NMRA United States
- Employees
- RIV N/A
- NMRA N/A
- Industry
- RIV Finance Companies
- NMRA
- Sector
- RIV Finance
- NMRA
- Exchange
- RIV Nasdaq
- NMRA Nasdaq
- Market Cap
- RIV 325.2M
- NMRA 268.5M
- IPO Year
- RIV N/A
- NMRA 2023
- Fundamental
- Price
- RIV $11.62
- NMRA $1.73
- Analyst Decision
- RIV
- NMRA Hold
- Analyst Count
- RIV 0
- NMRA 8
- Target Price
- RIV N/A
- NMRA $5.83
- AVG Volume (30 Days)
- RIV 87.6K
- NMRA 503.0K
- Earning Date
- RIV 01-01-0001
- NMRA 11-11-2025
- Dividend Yield
- RIV 12.85%
- NMRA N/A
- EPS Growth
- RIV N/A
- NMRA N/A
- EPS
- RIV N/A
- NMRA N/A
- Revenue
- RIV N/A
- NMRA N/A
- Revenue This Year
- RIV N/A
- NMRA N/A
- Revenue Next Year
- RIV N/A
- NMRA N/A
- P/E Ratio
- RIV N/A
- NMRA N/A
- Revenue Growth
- RIV N/A
- NMRA N/A
- 52 Week Low
- RIV $9.63
- NMRA $0.61
- 52 Week High
- RIV $12.43
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- RIV 27.17
- NMRA 47.30
- Support Level
- RIV $11.71
- NMRA $1.74
- Resistance Level
- RIV $11.98
- NMRA $1.90
- Average True Range (ATR)
- RIV 0.11
- NMRA 0.12
- MACD
- RIV -0.02
- NMRA -0.02
- Stochastic Oscillator
- RIV 10.56
- NMRA 10.94
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.